These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 33160530)

  • 1. Careful Selection of Patients Is Required to Obtain Higher Potential Benefit From Mepolizumab Therapy.
    Yılmaz İ
    Chest; 2020 Nov; 158(5):2229-2230. PubMed ID: 33160530
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient Selection for Mepolizumab in Severe Asthma: Time for Reappraisal?
    Kankaanranta H; Ilmarinen P
    J Allergy Clin Immunol Pract; 2020 Oct; 8(9):3009-3010. PubMed ID: 33039015
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic drug evaluation of mepolizumab for the treatment of severe asthma associated with persistent eosinophilic inflammation in adults.
    Kallur L; Gonzalez-Estrada A; Eidelman F; Dimov V
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1275-1280. PubMed ID: 29157020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mepolizumab-based therapy in asthma: an update.
    Walsh GM
    Curr Opin Allergy Clin Immunol; 2015 Aug; 15(4):392-6. PubMed ID: 26110690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mepolizumab: A Review in Eosinophilic Asthma.
    Deeks ED
    BioDrugs; 2016 Aug; 30(4):361-70. PubMed ID: 27311938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma.
    Gupta A; Pouliquen I; Austin D; Price RG; Kempsford R; Steinfeld J; Bradford ES; Yancey SW
    Pediatr Pulmonol; 2019 Dec; 54(12):1957-1967. PubMed ID: 31502421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
    Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
    J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mepolizumab effectiveness and identification of super-responders in severe asthma.
    Harvey ES; Langton D; Katelaris C; Stevens S; Farah CS; Gillman A; Harrington J; Hew M; Kritikos V; Radhakrishna N; Bardin P; Peters M; Reynolds PN; Upham JW; Baraket M; Bowler S; Bowden J; Chien J; Chung LP; Grainge C; Jenkins C; Katsoulotos GP; Lee J; McDonald VM; Reddel HK; Rimmer J; Wark PAB; Gibson PG
    Eur Respir J; 2020 May; 55(5):. PubMed ID: 32139455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Asthma: how does mepolizumab affect exacerbations and need for steroids? Mepolizumab is a new therapeutic option in severe asthma [corrected]].
    Taube C
    Dtsch Med Wochenschr; 2014 Nov; 139(47):2380. PubMed ID: 25390624
    [No Abstract]   [Full Text] [Related]  

  • 14. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
    Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
    Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study.
    Pelaia C; Busceti MT; Solinas S; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2018 Dec; 53():1-5. PubMed ID: 30217438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
    García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
    Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
    Comberiati P; McCormack K; Malka-Rais J; Spahn JD
    J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Stevenson M; Cooper K; Harnan S; Hamilton J; Clowes M; Carroll C; Harrison T; Saha S
    Pharmacoeconomics; 2018 Feb; 36(2):131-144. PubMed ID: 28933002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
    Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
    Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab versus placebo for asthma.
    Powell C; Milan SJ; Dwan K; Bax L; Walters N
    Cochrane Database Syst Rev; 2015 Jul; (7):CD010834. PubMed ID: 26214266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.